Evidence map›Paper›PMID 31407373›Full record

Trial reportAmerican journal of hematology2019

A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease.

Kenneth I Ataga, David Wichlan, Laila Elsherif, Vimal K Derebail, Adane F Wogu, Poulami Maitra, Jianwen Cai, Melissa C Caughey, David M Pollock, Jennifer S Pollock and 2 more

Open access · bronzeAbstract readLetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Interventions for chronic kidney disease in people with sickle cell disease.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Kenneth I AtagaCenter for Sickle Cell Disease, University of Tennessee Health Scienter Center, Memphis, Tennessee.ORCID 0000-0002-4501-9982
David WichlanDivision of Hematology/Oncology, University of North Carolina, Chapel Hill, North Carolina.
Laila ElsherifCenter for Sickle Cell Disease, University of Tennessee Health Scienter Center, Memphis, Tennessee.
Vimal K DerebailDivision of Nephrology and Hypertension, University of North Carolina, Chapel Hill, North Carolina.
Adane F WoguDepartment of Biostatistics, University of North Carolina, Chapel Hill, North Carolina.
Poulami MaitraDepartment of Biostatistics, University of North Carolina, Chapel Hill, North Carolina.
Jianwen CaiDepartment of Biostatistics, University of North Carolina, Chapel Hill, North Carolina.
Melissa C CaugheyDivision of Cardiology, University of North Carolina, Chapel Hill, North Carolina.
David M PollockDivision of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama.
Jennifer S PollockDivision of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama.
David R ArcherDepartment of Pediatrics, Emory University, Atlanta, Georgia.
Alan L HinderliterDivision of Cardiology, University of North Carolina, Chapel Hill, North Carolina.
University of North Carolina at Chapel Hill · USUniversity of Alabama at Birmingham · USUniversity of Tennessee Health Science Center · USEmory University · US

Funding

UNC CLINICAL AND TRANSLATIONAL SCIENCE AWARD: BPCAUL1RR025747 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUNGE, MARSCHALL S. · 2008 to 2011
$44.6M
The Role of Endothelin-1 in Sickle Cell DiseaseU01HL117684 · NHLBI · AUGUSTA UNIVERSITY · PI KUTLAR, ABDULLAH, MEILER, STEFFEN · 2013 to 2017
$8.1M
Targeted Anticoagulant Therapy for Sickle Cell DiseaseU01HL117659 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KEY, NIGEL S., MACKMAN, NIGEL · 2013 to 2017
$7.6M
Endothelial Dysfunction in the Pathogenesis of Sickle Cell NephropathyR01HL111659 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARCHER, DAVID R, ATAGA, KENNETH I · 2012 to 2016
$2.3M
NCRR NIH HHS UL1 RR025747NHLBI NIH HHS R01 HL111659NHLBI NIH HHS U01 HL117659NHLBI NIH HHS U01 HL117684
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AlbuminuriaAnemia, Sickle CellAtorvastatinEndothelium, VascularHydroxymethylglutaryl-CoA Reductase InhibitorsRenal CirculationRenal Insufficiency, ChronicAgedAngiotensin-Converting Enzyme Inhibitorsbeta-ThalassemiaCross-Over StudiesDouble-Blind MethodFemaleHumansHydroxyureaMaleAngiotensin-Converting Enzyme InhibitorsAtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxyurea

Identifiers

PMID31407373
PMCPMC12951693
OpenAlexW2968043255

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.